KA 2507 - Karus Therapeutics

Drug Profile

KA 2507 - Karus Therapeutics

Alternative Names: HDAC6 inhibitor; HDAC6i; KA2507

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karus Therapeutics
  • Developer Karus Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Depsipeptides; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 07 Aug 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Monotherapy) in USA (PO) (NCT03008018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top